Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Reich

Showing results (201-210 of 218) with videos related to

Pageof 22
Sort By:
The British Journal of Dermatology|February 26, 2016
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasisK A Papp, K Reich, C Paul, et al.
Contact Dermatitis|June 20, 1998
Genotype and phenotype of N-acetyltransferase 2 (NAT2) polymorphism in patients with contact allergyA Schnuch, G A Westphal, M M Müller, et al.
Archives of Dermatological Research|February 22, 2012
German S3-guidelines on the treatment of psoriasis vulgaris (short version)A Nast, W H Boehncke, U Mrowietz, et al.
Archives of Dermatological Research|September 22, 2010
Definition of treatment goals for moderate to severe psoriasis: a European consensusU Mrowietz, K Kragballe, K Reich, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 9, 2011
[New information about fumaric acid esters (Fumaderm): results of a workshop of experts]Ulrich Mrowietz, A Adamczyk, M Augustin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 13, 2017
European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPCA Nast, P I Spuls, G van der Kraaij, et al.
Archives of Dermatological Research|May 15, 2007
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)A Nast, I Kopp, M Augustin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 21, 2015
European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPCA Nast, P Gisondi, A D Ormerod, et al.
The British Journal of Dermatology|January 30, 2020
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsE L Simpson, J-P Lacour, L Spelman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 3, 2018
Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practiceJ-T Maul, A A Navarini, R Sommer, et al.
Pageof 22

Showing results (201-210 of 218) with videos related to

Sort By:
Pageof 22
The British Journal of Dermatology|February 26, 2016
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasisK A Papp, K Reich, C Paul, et al.
Contact Dermatitis|June 20, 1998
Genotype and phenotype of N-acetyltransferase 2 (NAT2) polymorphism in patients with contact allergyA Schnuch, G A Westphal, M M Müller, et al.
Archives of Dermatological Research|February 22, 2012
German S3-guidelines on the treatment of psoriasis vulgaris (short version)A Nast, W H Boehncke, U Mrowietz, et al.
Archives of Dermatological Research|September 22, 2010
Definition of treatment goals for moderate to severe psoriasis: a European consensusU Mrowietz, K Kragballe, K Reich, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 9, 2011
[New information about fumaric acid esters (Fumaderm): results of a workshop of experts]Ulrich Mrowietz, A Adamczyk, M Augustin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 13, 2017
European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPCA Nast, P I Spuls, G van der Kraaij, et al.
Archives of Dermatological Research|May 15, 2007
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)A Nast, I Kopp, M Augustin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 21, 2015
European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPCA Nast, P Gisondi, A D Ormerod, et al.
The British Journal of Dermatology|January 30, 2020
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsE L Simpson, J-P Lacour, L Spelman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 3, 2018
Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practiceJ-T Maul, A A Navarini, R Sommer, et al.
Pageof 22